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BACKGROUND & AIMS: Liver regeneration requires func-
tional liver macrophages, which provide an immune barrier
that is compromised after liver injury. The numbers of liver
macrophages are controlled by macrophage colony-
stimulating factor (CSF1). We examined the prognostic sig-
niﬁcance of the serum level of CSF1 in patients with acute
liver injury and studied its effects in mice. METHODS:
We measured levels of CSF1 in serum samples collected from
55 patients who underwent partial hepatectomy at the Royal
Inﬁrmary Edinburgh between December 2012 and October
2013, as well as from 78 patients with acetaminophen-
induced acute liver failure admitted to the Royal Inﬁrmary
Edinburgh or the University of Kansas Medical Centre.
We studied the effects of increased levels of CSF1 in uninjured
mice that express wild-type CSF1 receptor or a constitutive
or inducible CSF1-receptor reporter, as well as in chemokine
receptor 2 (Ccr2)-/- mice; we performed fate-tracing experi-
ments using bone marrow chimeras. We administered
CSF1-Fc (fragment, crystallizable) to mice after partial hepa-
tectomy and acetaminophen intoxication, and measured
regenerative parameters and innate immunity by clearance of
ﬂuorescent microbeads and bacterial particles. RESULTS:
Serum levels of CSF1 increased in patients undergoing
liver surgery in proportion to the extent of liver resected.
In patients with acetaminophen-induced acute liver failure, a
low serum level of CSF1 was associated with increased mor-
tality. In mice, administration of CSF1-Fc promoted hepatic
macrophage accumulation via proliferation of resident mac-
rophages and recruitment of monocytes. CSF1-Fc also pro-
moted transdifferentiation of inﬁltrating monocytes into cells
with a hepatic macrophage phenotype. CSF1-Fc increased
innate immunity in mice after partial hepatectomy or
acetaminophen-induced injury, with resident hepatic macro-
phage as the main effector cells. CONCLUSIONS: Serum CSF1
appears to be a prognostic marker for patients with acute liverinjury. CSF1 might be developed as a therapeutic agent to
restore innate immune function after liver injury.Keywords: Drug-Induced Liver Damage; Clearance; Immune
Response; M-CSF.he liver provides an essential immune barrierTagainst gut-derived pathogens entering the portal
circulation.1 Although surgical removal of liver tissue (par-
tial hepatectomy) results in rapid compensatory up-
regulation of metabolic function, the liver’s innate immune
capacity is markedly impaired.2,3 Acute toxic liver injury
leads to widespread hepatocyte necrosis and compromises
barrier function.4 Changes in gut wall integrity associated
with liver failure facilitate the translocation of gut-derived
pathogens.5 Consequently, sepsis is common in patients
with liver failure and is strongly associated with high
mortality rates.6,7 Liver transplantation is the only effective
therapy for life-threatening liver failure but active sepsis is
contraindicated in transplantation.
Hepatic macrophages mediate hepatic innate immune
defense and promote hepatocyte proliferation after liver
injury.8,9 Tissue macrophage numbers are controlled
during development, and in the steady state, by macrophage
colony-stimulating factor (CSF1), which acts through a
tyrosine kinase receptor, colony-stimulating factor receptor
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macrophages and impaired liver regeneration after partial
hepatectomy.12 Hepatic macrophages control circulating CSF1
levels via receptor-mediated endocytosis through CSF1R.13 In
human beings after living donor partial hepatectomy,
increased circulating CSF1 is associated with more rapid liver
regrowth.14 In acute toxic liver injury models, monocyte-
derived macrophage recruitment is required for necrotic
tissue resorption.15 In human acute liver injury, hepatic mac-
rophages are implicated in tissue repair and low monocyte
counts are associated with mortality.16,17 Based on these
ﬁndings there is a strong rationale for exploring the potential of
macrophage-based therapeutics to improve outcomes after
acute liver injury.
Here, we show that high serum CSF1 level is associated
with survival in patients with acute liver failure (ALF) and
outperforms previous markers of outcome in terms of
discriminative ability. We show that CSF1 administration in
animal disease models promotes rapid recovery of innate
immune function and hence has therapeutic potential in
human liver failure.
Materials and Methods
Human Work
Ethical approval was obtained from the South East Scotland
Research Ethics Committee for patients undergoing partial
hepatectomy (PH) at the Hepatobiliary Unit, Royal Inﬁrmary
Edinburgh, between December 2012 and October 2013. Liver
failure was deﬁned according to Schindl et al.7 For the
acetaminophen-induced ALF cohort, ethical approval was gran-
ted by the local human research ethics committee and informed
consent was obtained from all patients, or next of kin, before
study entry. This study built on previous analysis of this patient
cohort by Antoine et al,18 representing 78 adult patients
admitted to the Royal Inﬁrmary Edinburgh (United Kingdom), or
the University of Kansas Medical Center (United States), with
acute liver injury. Serial patient samples from a second patient
cohort were collected at admission to the hospital (as opposed to
admission to the specialist liver center with acute liver failure).18
Details of serum analyses are provided in the Supplementary
Materials and Methods section. Primary hepatocytes were iso-
lated from human liver tissue obtained from liver resection
specimens immediately after surgery, with full informed consent
and ethical approval from the relevant authorities (National
Research Ethics Service reference: 11/NW/0327). See the
Supplementary Materials and Methods section for assay details.
Animal Experiments
Animalprocedureswere approvedby the relevant institutional
ethics committee (Albert Einstein College of Medicine, United
States; University of Edinburgh, United Kingdom; and the Univer-
sity of Glasgow, United Kingdom), and adhered to the Animals
(Scientiﬁc Procedures) Act of 1986 (United Kingdom) and the
National Institutes of Health guide for the Care of Laboratory An-
imals (United States). Eight- to 12-week-old male mice were
used for all experiments. CCR2-/-, C57Bl/6, and MacGreen mice
(Tg[Csf1R-Green ﬂuorescent protein]Hume
19) were bred and
maintained under speciﬁc pathogen-free conditions. Tg(Csf1r-
Mer2iCre)jwp were crossed to Rosa ﬂoxed stop tomato red andlineage tracing experiments performed asdescribed.20 Fate tracing
bone marrow–derived monocytes was performed using a mouse
chimera as previously described.21 Wild-type C57BL/6 mice were
obtained from Charles River (Margate, Kent, UK). Mice were
distributed randomly and maintained on A 12-hour light-dark
cycle with feed ad libitum. A two-thirds partial hepatectomy was
performed as previously described.22 Acetaminophen intoxication
involved intraperitoneal administration of 350 mg/kg acetamin-
ophen (Sigma-Aldrich, St. Louis, MO).23 The treatment group
received 0.75 mcg/g CSF1-Fc, prepared as described previously24
(control: phosphate-buffered saline), administered subcutane-
ously immediately after partial hepatectomy or 12 hours after
acetaminophen intoxication and subsequently every 24 hours for
up to 3 further doses. Reagents and methodology for immuno-
histochemistry, ﬂow cytometry, quantiﬁcation of messenger RNA
(mRNA), phagocytosis assay, and serum analyses are provided in
the Supplementary Materials and Methods section.
Hepatocyte Toxicity and Metabolic Assays
Details of human and mouse hepatocyte toxicity and
metabolic assays are provided in the Supplementary Materials
and Methods section.
Statistics
Statistical analysis was performed on GraphPad Prism V6.0
(GraphPad Software, Inc, La Jolla, CA), except for logistic regres-
sion analyses, which were conducted in R.25 All data are pre-
sented as mean ±SEM unless otherwise stated. Two-tailed
Student t test and 1-way and 2-way analysis of variance with
Bonferroni adjustment were used for analysis of data. Human
serum analyses and development of the logistic regression
models were completed by a qualiﬁed statistician. The level of
signiﬁcance was set at a P value less than .05 for all analyses.
Results
Serum CSF1 Increases According to Extent
of Partial Hepatectomy and Is Associated
With Survival in Acute Liver Failure
In a cohort of 55patients undergoingup to75%PH(cohort
details: Supplementary Figure 1A), serumCSF1was increased
signiﬁcantly compared with healthy controls. There was a
small reduction on day 1 after surgery followed by a marked
increase in CSF1 level by postoperative day 3 (Figure 1A).
Therewas no correlation between serumCSF1 level and blood
loss (Supplementary Figure 1B). The initial decrease in serum
CSF1 level may be owing to removal of tumor cells, which
secrete CSF1.26We hypothesized that the subsequent increase
in serum CSF1 level might be produced by proliferating he-
patocytes. Because of the risks associated with liver biopsy in
human beings, we examined a mouse model of two-thirds PH.
CSF1 mRNA was unchanged after PH (Supplementary
Figure 1C). In the patient cohort the CSF1 increase was
related to the extent of resection (Figure 1B). Two patients
developed postoperative liver failure and both had serum
CSF1 levels below the 25th percentile (Figure 1C, and the
clinical details are shown in Supplementary Figure 1D).
We sampled serum from a large patient cohort with
established acetaminophen-induced ALF on arrival at the
Figure 1. Serum CSF1
level increases after partial
hepatectomy in human be-
ings according to the
extent of resection. (A)
Serum CSF1 in healthy
volunteers and patients
undergoing partial hepa-
tectomy to remove cancer.
(B) Mean serum CSF1
categorized according to
extent of resection. (C)
Box plots and whisker
plots showing minimum
to maximum values, with
patients developing post-
operative liver failure over-
laid with red dots. *P < .05,
** P < .01, *** P < .001, ****
P < .0001.
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The assessment of ALF and the requirement for liver trans-
plantation currently is based on the validated modiﬁed
King’s College Hospital criteria, which reﬂect poor clinical
condition and likelihood of death. Low serum CSF1 was
associated signiﬁcantly with patient deterioration to meet
King’s College Hospital criteria (Supplementary Figure 2B
and C), and subsequent death or liver transplantation
(Figure 2A). Regardless of ﬁnal outcome, those patients with
a Systemic Inﬂammatory Response Score27 greater than 2
had a signiﬁcantly lower CSF1 level (Supplementary
Figure 2D). Serial samples in a separate patient cohort (de-
tails shown in Supplementary Figure 2E), followed up from
ﬁrst presentation to hospital, showed that serum CSF1 levels
continued to increase in patients whose liver regenerated,
whereas CSF1 levels decreased in patients who deteriorated(Figure 2B). In the livers removed from transplant recipients,
CSF1 was detected in hepatocytes and nonparenchymal cells
(Supplementary Figure 2E). Given the risks of liver biopsy,
we used the mouse model to assess hepatic CSF1 gene
expression. In contrast to PH, hepatic CSF1 mRNA expression
increased signiﬁcantly after acetaminophen intoxication,
peaking at day 2 (Supplementary Figure 2F).
The current best available prognostic biomarker in ALF is
serum acetyl-high mobility group box-1 (HMGB1).18 This
damage-associated molecular pattern is released from
necrotic tissue and by activated immune cells in response to
injury.28 We assessed the discriminative ability of acetyl-
HMGB1, alongside CSF1, and also established clinical mea-
sures including bilirubin, prothrombin time, and alanine
aminotransferase (ALT) level using the receiver operator
characteristic curve (Figure 2C). Serum CSF1 and acetyl-
December 2015 CSF1 Indicates Outcome in Liver Failure 1899HMGB1 show similar proﬁles, whereas bilirubin, PT, ALT, and
Acute Physiology and Chronic Health Evaluation II (APACHE
II) score were of limited value. There was an inverse corre-
lation between CSF1 and acetyl-HMGB1 (Figure 2D). When
combined in a logistic regression model, only CSF1 showed
signiﬁcance (Figure 2E and Supplementary Figure 2F), indi-
cating that serum CSF1 level was a better predictor of
outcome than acetyl-HMGB1 (Supplementary Figure 2G and
H). Figure 2F provides example CSF1 values with risk of death
based on the CSF1 alone model.BA
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Hepatic Enlargement Involving Macrophage
Accumulation in Mice
The association of low serumCSF1with poor prognosis in
ALF provides a rationale for therapeutic use. Some studies
have reported that CSF1R is expressed outside the macro-
phage lineage.29,30 We therefore examined CSF1R expression
using MacGreen mice, where enhanced green ﬂuorescent
protein (eGFP) is under the control of the Csf1r promoter.19
Multiphoton ex vivo imaging of liver conﬁrmed CSF1R
expression limited to cells with tissue macrophage
morphology (Figure 3A). To conﬁrm this, we crossed Csf1r-
Mer-Cre-Mer to Rosa26-LSL-dTom reporter mice to allow
tamoxifen-induced labeling of CSF1Rþ cells, as previously
described.20 Co-localization of the pan-macrophage marker
F4/80 conﬁrmed that all dTomatoþ (CSF1Rþ) cells belonged
to the macrophage lineage (Figure 3B). These data are sup-
ported by expression proﬁling from the Functional Annota-
tion of Mammalian Genomes 5 (FANTOM5) consortium,
which show no detectable CSF1R mRNA in hepatocytes iso-
lated from control, or regenerating, mouse liver or isolated
human hepatocytes.31
To assess the therapeutic potential of CSF1, we used the
CSF1-Fc fusion protein, which overcomes the short half-life
of CSF1 protein in vivo.24 CSF1-Fc treatment of mice pro-
moted hepatic macrophage accumulation, but the mecha-
nisms were unclear.24,32 Six hours after CSF1-Fc
administration to uninjured mice there was a marked up-
regulation of hepatic chemokines, particularly CCL2, CCL7,
and CCL12, which are ligands for the CCR2 receptor and
highly expressed by classic (Ly6Cþ) blood monocytes
(Figure 3C, and array details are shown in Supplementary
Figure 3A). After 4 days of CSF1-Fc treatment, 20% of the
liver was composed of F4/80þ macrophages compared with
2% in steady state (Figure 3D). This macrophage accumu-
lation initiated hepatocyte proliferation at day 4.24 Mecha-
nisms of hepatocyte proliferation are multifactorial, with an
up-regulation of many cytokines and chemokines associ-
ated with the inﬂammatory response.24 Despite the induc-
tion of proinﬂammatory cytokine mRNA in the liver, serum
ALT and aspartate aminotransferase levels were reduced
with CSF1-Fc treatment, whereas bilirubin level was un-
changed (Figure 3F) and there was no hepatocyte apoptosis
(Supplementary Figure 3B). The spleen increased in size,
although the weights of the other organs did not change
(Supplementary Figure 3C and D).Macrophage Accumulation Involves In Situ
Proliferation and CCR2-Related Inﬁltration
Inﬁltrating monocyte-derived macrophages and tissue
resident macrophages can be distinguished by relative
expression of F4/80 and CD11b and may remain
distinctly regulated entities in steady-state liver and after
acetaminophen-induced injury.20,33–35 After CSF1-Fc treat-
ment, there was a 2-fold increase in cells with a resident
hepatic macrophage phenotype (F4/80hiCD11blo) and
more than a 5-fold increase in the monocyte-derived inﬁl-
trating macrophages (F4/80loCD11bhi cells), consisting
predominantly of Ly6Chi monocytes (Figure 4A). Both
F4/80hiCD11blo and F4/80loCD11bhi cells proliferated
markedly in situ after CSF1-Fc administration (Figure 4B
and Supplementary Figure 4A and B). Liver macrophages in
the treated livers were fate-mapped using tissue-protected
bone marrow chimeric mice, where only the hind legs of
recipient CD45.1þCD45.2þ animals were irradiated before
engraftment of congenic CD45.1þ bone marrow. In these
animals, F4/80loCD11bhi macrophages and blood mono-
cytes showed equivalent donor chimerism (Figure 4C). In
phosphate-buffered saline–treated animals, F4/80hi/
CD11blo cells remained almost exclusively of host origin,
consistent with their proposed tissue origin.20,33,34 Howev-
er, after CSF1-Fc treatment, approximately 20% of the F4/
80hi/CD11blo cells were derived from recruited cells. Thus,
the increase in liver macrophages resulted from inﬁltration
of monocytes, proliferation of inﬁltrating and resident cells,
as well as a minor role for differentiation of inﬁltrating
macrophages into a resident macrophage phenotype.
The only other cell population that increased signiﬁcantly
was eosinophils (Supplementary Figure 4C), which may
have responded to eosinophil chemoattractants CCL3, 4, 7,
and 12, detected 6 hours after CSF1-Fc administration
(Figure 3C).
Ligands for the CCR2 receptor, which are potentmonocyte
chemoattractants, were up-regulated early after CSF1-Fc
administration (Figure 3A). To examine the role of recruited
monocytes, we tested CSF1-Fc administration on Ccr2-/- mice,
hypothesizing that the mobilization and recruitment of inﬁl-
trating F4/80lo CD11bhi macrophages would be prevented
because Ly6Chi monocytes are thought to depend on CCR2
signals for release from the bone marrow and extravasation
into inﬂamed tissues.15,36 Surprisingly, Ccr2-/- mice devel-
oped a pronounced Ly6Chi monocytosis after CSF1-Fc
administration, indicating that CSF1 can overcome the CCR2
requirement for marrow release (Supplementary Figure 4D).
Nevertheless, CSF1-Fc–driven hepatic engraftment by inﬁl-
trating macrophages was reduced by CCR2 deﬁciency
(Figure 4D). Accumulation of resident F4/80hiCD11blo mac-
rophages was largely unaffected, consistent with local pro-
liferation being themajormeans of expansion. The increase in
eosinophils was unaffected by CCR2 deﬁciency. CSF1-Fc
treatment increased hepatic neutrophils in CCR2 deﬁciency
(Supplementary Figure 4E), probably owing to the deﬁcit in
inﬁltrating monocytes, which regulate neutrophil activity.35
Importantly, CCR2 deﬁciency prevented the increase in
liver-to–body weight ratio observed in wild-type mice after
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Figure 3. Hepatic enlarge-
ment after CSF1R
stimulation. (A) Repre-
sentative multiphoton im-
age of ex vivo liver
(MacGreen mouse Tg
[CSF1r-GFP]Hume). (B)
Representative immunoﬂu-
orescence images ofCsf1r-
Mer2iCreJWP Rosa ﬂoxed
stop tomato red after in-
duction. (C) Cytokine/che-
mokinearray of liver tissue6
hours after CSF1-Fc treat-
ment vs control (n ¼ 4/
group). (D) Quantiﬁcation of
hepatic F4/80 immunohis-
tochemistry in phosphate-
buffered saline (PBS)
control-treated (n ¼ 8) and
mice treated with CSF1-Fc
for 2 or 4 days (n ¼ 4/
group). (E) Quantiﬁcation of
hepatocyte proliferation in
control-treated mice and at
day 2 and day 4 after CSF1-
Fc administration (20 high-
power ﬁelds/mouse). (F)
Serum parameters after 4
days CSF1-Fc (grey, hollow
circles) or PBS control
(black, solid circles) treat-
ment once daily (2-way
repeated-measures anal-
ysis of variance with Bon-
ferroni post hoc). Alk
phos, alkaline phospha-
tase; Creat, creatinine. *P<
.05, ** P < .01, *** P < .001,
**** P < .0001.
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CD11bhi macrophages are not completely dependent on CCR2
for mobilization and trafﬁcking to tissues, the data suggest=
Figure 2. High serum CSF1 level is associated with survival in
healthy volunteers and in patients after acetaminophen intoxica
liver transplantation, n ¼ 31). (B) Serial CSF1 samples of pa
intoxication (n ¼ 10/group). (C) Receiver operator characteristic c
time (PT), ALT, bilirubin, and APACHE II score with areas under
died/required liver transplantation. (D) Dot plot of serum CSF
specialist liver center (slope difference: F ¼ 0.15, P ¼ .70; interce
logistic regression model. (F) Example of serum values and pred
CSF1 alone (model 2). *P < .05, ** P < .01, *** P < .001, **** Pthe action of CSF1-Fc on monocyte-derived rather than resi-
dent macrophages is the critical step promoting hepatic
enlargement.acute liver failure in human beings. (A) Serum CSF1 level in
tion on arrival to a specialist liver unit (survived, n ¼ 47; died/
tients on ﬁrst presentation to hospital after acetaminophen
urve for serum CSF1, acetyl-HMGB1 (aHMGB1), prothrombin
curve (AUC value) for patients who subsequently survived or
1 level vs log(serum acetyl-HMGB1) on presentation to the
pt difference: F ¼ 8.03, P ¼ .006). (E) Details of the combined
icted chance of death based on logistic regression involving
< .0001.
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Figure 4. CSF1-receptor stimulation recruits monocytes and induces macrophage proliferation in uninjured mouse liver. (A)
Number of hepatic macrophage populations (F480hi/CD11blo and F480lo/CD11bhi) day 2 after CSF1-Fc administration (n ¼ 8/
group) relative to mean of control group and representative Ly6C proﬁle of F480hi (red) and F480lo (blue) populations. (B)
Percentage of hepatic macrophage populations expressing markers of proliferation (Ki67 and bromodeoxyuridine [BRDU]) on
day 2 after CSF1-Fc administration relative to the mean of the control group. (C) Fate tracing bone marrow–derived monocytes
using chimeric mice showing conversion of inﬁltrating cells to resident macrophage phenotype driven by CSF1-Fc. The
percentage of cells derived from blood monocytes was based on the ratio of chimerism in hepatic populations to chimerism in
circulating blood monocytes. (D) Number of hepatic macrophage populations on day 2 after CSF1-Fc administration in wild-
type (WT) and CCR2-/- mice (n ¼ 8/group), with representative Ly6C proﬁle of F480hi (red) and F480lo (blue) populations (solid,
CCR2-/-; dotted line, WT). (E) Liver weight to body weight ratio after 2 days of control (black) or CSF1-Fc administration (grey)
in wild-type and CCR2-/- mice (n ¼ 8/group). *P < .05, ** P < .01, *** P < .001, **** P < .0001.
Figure 5. CSF1-Fc en-
hances hepatic phagocytic
capacity after partial hepa-
tectomy in mice. (A) Liver
weight to body weight ratio
after PH with CSF1-Fc or
control (n ¼ 8/group). (B)
Ki67þ hepatocytes per
high-power ﬁeld after PH
(n¼ 8/time point/group). (C)
Number of resident (red) or
inﬁltrating (blue) hepatic
macrophage populations
on day 2 after PH and
CSF1-Fc administration.
Representative dot plots
of hepatic macrophage
proﬁle and representative
Ly6C proﬁle normalized to
mode. (D) Hepatic gene
expression of phagocytic
markers macrophage re-
ceptor with collagenous
structure (MARCO), macro-
phagescavenger receptor1
(MSR1), and mannose re-
ceptor (MR) vs relevant
control. (E) Multiphoton im-
age of ex vivo Csf1r-eGFP
mouse liver after injection
of ﬂuorescent microbeads
and clearance from the cir-
culation following sham or
two-thirds PH with control
or CSF1-Fc (n ¼ 6/group/
time point). (F) Net ﬂuores-
cence liver, spleen, lung,
kidney, and brain on day 2
after PH and CSF1-Fc or
control (n¼ 6 per group). *P
< .05, ** P < .01, *** P <
.001, **** P < .0001.
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Innate Immune Capacity After Partial Hepatectomy
Patient survival depends on the rapid restoration of
liver macrophage functions to clear pathogenic material. Wetherefore tested the effect of CSF1-Fc on innate immune
function in injury models. CSF1-Fc administration increased
liver size over controls at 4 days after PH (Figure 5A).
Hepatocyte staining (CYPD2) per unit area (Supplementary
Figure 7. CSF1-Fc and
acetaminophen intoxica-
tion in mice. (A) Liver
weight to body weight
ratio with CSF1-Fc or
control. (B) Representative
immunohistochemistry F4/
80 (red) and Ki67 (3,30-
diaminobenzidine [DAB])
at day 2 and day 4
after acetaminophen with
phosphate-buffered saline
control or CSF1-Fc. (C)
Hepatic expression of
phagocytosis-associated
genes after GW2580
(red), AFS98 (blue), or
CSF1-Fc (grey) relative to
the mean of the control
group (vehicle, rat IgG2a,
phosphate-buffered sa-
line, respectively). (D) Net
ex vivo liver ﬂuorescence
15 minutes after injection
of ﬂuorescent beads. (E)
Serum liver–associated
biochemistry tests at day
3 after acetaminophen
intoxication and either
GW2580 (red), AFS98
(blue), or CSF1-Fc (grey)
compared with control
(vehicle, rat IgG2a,
phosphate-buffered saline,
respectively). MARCO,
macrophage receptor with
collagenous structure; MR,
mannose receptor; MSR1,
macrophage scavenger re-
ceptor 1. *P < .05, ** P <
.01, *** P < .001, **** P <
.0001.
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cating the increased size was owing to increased non-
parenchymal cell accumulation. Peak hepatocyte proliferation
(day 2) was not increased by CSF1-Fc treatment (Figure 5B),=
Figure 6. Contribution of hepatic phagocytes to clearance o
macrophages (F4/80 ¼ green) after isolation by adherence and
number and percentage of resident macrophages phagocytosing
MA). Representative density plots of phagocytic cells in the resid
macrophages phagocytosing E coli bioparticles compared with
phagocytosing E coli particles according to Ly6C expression statu
the liver with a bar chart showing the absolute cell number compa
eosinophils. Eos, eosinophils; Neuts, neutrophils. *P < .05, ** P <although at later time points the macrophage accumulation
did promote increased hepatocyte proliferation compared
with controls. To conﬁrm the role of endogenous CSF1
signaling, implied from studies of op/op mice,12 we treatedf pathogenic material. (A) Immunohistochemistry of hepatic
administration of E coli bioparticles (pHrodo) (red). (B) Relative
E coli bioparticles (pHrodo, ThermoFisher Scientiﬁc, Waltham,
ent macrophage population. (C) Relative number of inﬁltrating
the mean of the control group with the percentage of cells
s. (D) Pie charts illustrating the proportion of phagocytic cells in
rison for resident and inﬁltrating macrophages, neutrophils, and
.01, *** P < .001, **** P < .0001.
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body against the CSF1 receptor (AFS98). Both treatments
reduced hepatocyte proliferation (Supplementary Figure 5B)
and affected the expression of macrophage-related cytokine
and matrix remodeling genes associated with regeneration
(Supplementary Figure 5C and D).
After PH, macrophages accumulated more rapidly in the
liver of CSF1-Fc–treated mice, involving both monocyte-
derived inﬁltration and proliferation (Figure 5C). There
was a corresponding increase in genes encoding phagocytic
receptors,37,38 such as macrophage receptor with collage-
nous structure and macrophage scavenger receptor 1, with
a reciprocal reduction after CSF1 blockade (Figure 5D). To
assess the impact on clearance of insoluble material and
bacteria-derived particles, we injected ﬂuorescent-labeled
latex microbeads intravascularly. These were rapidly and
selectively taken up by liver phagocytes. There was mini-
mal uptake by the spleen, lung, kidney, brain, and circu-
lating cellular populations (Supplementary Figure 5E–G).
Multiphoton imaging of the Csf1r-eGFP mouse liver
conﬁrmed that microbeads were phagocytosed by hepatic
macrophages with CSF1-Fc treatment, causing enhanced
clearance from the circulation (Figure 5E). Ex vivo whole-
organ ﬂuorescence imaging indicated this enhanced clear-
ance capacity was clearly due to liver uptake (Figure 5F).
To extend these ﬁndings to potential pathogens, we used
pH-sensitive Escherichia coli bioparticles that ﬂuoresce
when taken up into acidiﬁed vesicles and injected these
into the portal vein (Figure 6A). CSF1-Fc treatment
increased both the internalization capacity and the abso-
lute yield of positive cells (Figure 6B). Relatively few
inﬁltrating monocyte-derived cells (F4/80lo CD11bhi)
internalized the labeled E coli, but CSF1-Fc treatment again
increased the clearance capacity (Figure 6C). The Ly6Clo
monocyte population consistently showed a greater pro-
pensity for phagocytosis compared with the Ly6Chi popu-
lation based on the percentage of the populations
phagocytosing the E coli particles both in the control and
CSF1-Fc–treated groups (Figure 6C). The resident F4/80hi
CD11blo cells remained the dominant phagocyte in the liver
(Figure 6D).The Impact of CSF1-Fc on
Acetaminophen Toxicity
The predictive value of serum CSF1 levels in patients
with ALF, and the ability of CSF1-Fc to promote regenera-
tion and improve clearance functions, suggests therapeutic
potential in acetaminophen toxicity. Macrophage accumu-
lation, proliferation of resident macrophages, and inﬁltra-
tion of monocyte-derived macrophages is essential for
recovery and subsequent regeneration after acetaminophen
administration to mice.16,35 Enhanced macrophage accu-
mulation could facilitate recovery by rapidly clearing
necrotic debris and restoring hepatic immune function. We
treated mice with CSF1-Fc 12 hours after acetaminophen
intoxication, the point of maximal injury.39 CSF1-Fc treat-
ment expanded the macrophage compartment and
increased the liver weight to body weight ratio (Figure 7A).CSF1-Fc increased macrophage accumulation at the area of
necrosis (Figure 7B), without signiﬁcantly increasing the
affected area (Supplementary Figure 6A). In control-treated
animals there was a predominance of inﬁltrating monocytes
relative to resident hepatic macrophages as previously
described,15 and both of these populations were boosted by
CSF1-Fc (Supplementary Figure 6B). Expression of mRNA
for clearance receptors (macrophage receptor with collag-
enous structure and macrophage scavenger receptor) was
enhanced in the livers of CSF1-Fc–treated animals
(Figure 7C), associated with an increase in the phagocytic
capacity of the liver detected using injected microbeads
(Figure 7D). Despite the profound macrophage changes in
the liver, serum cytokines were unaffected by CSF1-Fc
treatment (Supplementary Figure 6C). Increased macro-
phage recruitment did not produce additional injury. Serum
injury markers (ALT, alkaline phosphatase) decreased in
CSF1-Fc–treated mice, with reciprocal change after CSF1R
blockade (Figure 7E and Supplementary 7F and G). These
ﬁndings most likely reﬂect changes in the clearance of these
enzymes by hepatic macrophages40 (Figure 7C). Serum al-
bumin level was reduced by CSF1-Fc treatment, likely a
reﬂection of the proinﬂammatory state given that hepatic
albumin gene expression was unchanged from control
(Supplementary Figure 6D). Serum total protein also was
unchanged (Supplementary Figure 6E). To further explore
the potential direct effects of CSF1-Fc on hepatocytes we
assessed hepatocyte viability and performed metabolic as-
says, which showed no direct effect of CSF1-Fc on either
mouse or human hepatocytes (Supplementary Figure 7A
and B). Furthermore, after acetaminophen intoxication in
mice, there was no change in cytochrome p-450 activity
assessed by CYP2E1 expression with CSF1-Fc treatment
(Supplementary Figure 7C).Discussion
We have shown a clear association between reduced
serum CSF1 level and poor outcome in acute liver failure
in human beings. CSF1-Fc treatment produced hepatic
macrophage accumulation through in situ macrophage
proliferation and recruitment of monocyte-derived cells
in mouse models. Resident macrophages in the mouse are
largely maintained through self-renewal.33 Fate mapping
of hematopoietic cells indicated that CSF1-Fc also
can drive conversion of circulating monocytes to cells of
a resident macrophage phenotype. This novel ﬁnding
shows the plasticity in the resident and inﬁltrating
macrophage compartments and provides new evidence
that bone marrow–derived macrophages can contribute to
the resident macrophage population given appropriate
stimuli.
CSF1-Fc–driven hepatic macrophage accumulation
enhanced innate immune capacity in mouse models of liver
injury. After PH, the therapeutic requirement to optimize
liver function and boost regeneration must be weighed
against the potential to promote cancer recurrence. Malig-
nant tumors themselves can produce CSF1, which mediates
macrophage accumulation, supporting tumor growth.41
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situ had increased serum CSF1 levels. However, effective
elimination of circulating tumor cells, which are indicative
of recurrence, requires hepatic macrophages, which depend
on CSF1.10,42,43 The ability to enhance the innate immune
capacity of the liver by increasing hepatic macrophage
density may be valuable from an antimicrobial standpoint
and theoretically may reduce cancer recurrence rates, which
can reach 60%.44
ALF represents a different clinical challenge to PH. The
low serum CSF1 level in those who required liver trans-
plantation or died in our patient cohort is consistent with
the monocytopenia described in ALF, particularly given the
persistence of monocyte precursors in the bone
marrow.16,17 Monocytes express low levels of HLA-DR in
ALF, which can impair the response to sepsis.17 Together
with our results, these ﬁndings indicate that supplementary
CSF1 therapy in the setting of low serum CSF1 levels might
facilitate recovery by increasing monocyte numbers, induce
a proregenerative macrophage phenotype, increase mono-
cyte HLA-DR expression,45 and enhance phagocytic capacity.
Multiorgan involvement is characteristic of clinical deterio-
ration in ALF and previous reports implicating CSF1
signaling in recovery after both kidney and brain injury
highlight potential wider beneﬁts of this strategy.30,46 The
ability to predict patient deterioration, using a marker such
as CSF1, before meeting the current clinical criteria for
transplantation (King’s College Hospital criteria) could
facilitate the earlier stratiﬁcation of patients with the
greatest need. It would be interesting to study the role of
CSF1 in acute-on-chronic liver failure, in which innate im-
munity may be impaired.
There is mounting evidence for a CSF1–CCR2 axis in
monocyte recruitment with the induction of these factors
after acute hepatic injury.35 The chemokine signaling
induced in the liver after CSF1-Fc administration was not
restricted to the CCR2 receptor, and monocyte extravasa-
tion into the liver parenchyma was impaired, but not
prevented by the CCR2 deﬁcit, suggesting that CSF1-Fc
either mobilizes monocytes from other sources (eg, the
spleen) or overcomes the CCR2 dependence on bone
marrow release.
In contrast to PH, in which the increase in available
CSF1 is related to reduced clearance, in acute liver toxicity
hepatic CSF1 mRNA increased (Supplementary Figure 2C).
Evidence of local production also was seen in the liver of
patients (Supplementary Figure 2D). The increased local
hepatic CSF1 production may drive macrophage accumu-
lation during the early response to injury, when phagocy-
tosis is essential to clear dying hepatocytes. As well as the
improved clearance of insoluble and infective material to
reduce the risk of sepsis, macrophages also might promote
clearance of circulating tumor cells. Some of the earliest
studies of CSF1 treatment showed an impact on tumor
metastasis.29 CSF1-Fc already has been shown to be safe in
pigs,24 and the native protein was tested previously by
continuous infusion in human phase 1 trials and was well
tolerated.47In summary, we have shown that increased serum CSF1
is an important response to liver injury, and impairment of
this response is associated with poor outcome in acute liver
failure. Serum CSF1 response after liver injury could be used
to stratify patients according to severity and to identify
candidates for CSF1 therapy.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
j.gastro.2015.08.053.References
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Supplementary Materials and Methods
Human Serum Samples
Serum samples were blinded and cytokine analysis was
completed in a random order. Serum CSF1 was analyzed
using the Meso Scale Discovery CSF1 immunoassay and
analyzed on a Meso QuickPlex SQ120 (Meso Scale Diagnostics,
Rockville, MD). Serum acetyl-HMGB1 was analyzed by mass
spectrometry.
Clinical Scoring
King’s college criteria in the context of acetaminophen-
induced liver failure was deﬁned as arterial pH less than
7.3, international normalized ratio greater than 6.5, serum
creatinine level greater than 300, and the presence of en-
cephalopathy.1 The systemic inﬂammatory response criteria
were met when 2 or more of the following occurred: body
temperature higher than 38C or less than 36C, heart rate
faster than 90 beats per minute, respiratory rate greater
than 20 breaths per minute, or white blood cell count greater
than 12,000/cf mm or less than 4000/cf mm.2 The APACHE
II score was calculated as previously described.3
Reagents
CSF1-Fc is a conjugate of porcine CSF1 with the Fc region
of porcine IgG1A (43.82 kilodaltons total) produced by Zoetis
(Florham Park, NJ) for D. Hume (UK patent application
GB1303537.1). Porcine CSF1 is equally active in mice.4 The Fc
conjugate provides increased circulating half-life. CSF1-Fc did
not show any endotoxin-like activity in murine bone
marrow–derived macrophages.5 CSF1-receptor blockade was
induced by the CSF1R tyrosine kinase inhibitor, GW2580 (160
mg/kg suspended in 0.5% hydroxypropylmethylcellulose and
0.1% Tween 80,5 LC Laboratories, Woburn, MA), or using the
antibody AFS98 produced by Sudo et al,6 and provided by
BioServ UK (Shefﬁeld, Yorkshire, UK). CSF1-Fc, GW2580, and
AFS98 were administered immediately after two-thirds par-
tial hepatectomy or 12 hours after acetaminophen intoxica-
tion (point of maximal injury7).
Collection of Mouse Tissues
Mice were culled via CO2 inhalation and after a midline
laparotomy blood was aspirated from the inferior vena cava for
serum analysis. Mice were perfused through the inferior vena
cava and viscera were excised and weighed. Viscera were either
ﬁxed in 4% formalin for immunohistochemistry, placed in RNA
later (Life Technologies, ThermoFisher Scientiﬁc, Waltham,
MA), or placed in phosphate-buffered saline for ﬂow cytometry.
Immunohistochemistry
Sections of formalin-ﬁxed tissue (3 mm) were used for
immunostains. Ki67, bromodeoxyuridine, and CYPD2
required heat-mediated antigen retrieval with 0.01 mol/L
sodium citrate, pH 6.0, for 10 minutes. Primary antibodies
were used at the following dilutions: Ki67 (Leica Micro-
systems, Wetzlar, Germany) 1:500, bromodeoxyuridine
(Abcam, Cambridge, UK) 1:100, F4/80 (clone CI:A3-I; Bio-
legend, San Diego, CA) 1:100, and CYPD2 (Abcam) 1:100.
Appropriate secondary antibody was applied at a 1:250 dilu-
tion. Dual immunohistochemistry with F4/80 and bromo-
deoxyuridine or Ki67 was performed by ﬁrst developing F4/
80 using the tyramide signal ampliﬁcation system (Perki-
nElmer, Waltham, MA) with subsequent heat-mediated anti-
gen retrieval followedbybromodeoxyuridine orKi67 staining.
Ki67 and F4/80 dual immunohistochemistry also was per-
formed by developing F4/80 with an alkaline phosphatase
substrate kit (red, Vector Laboratories, Burlingame, CA), and
after heat-mediated antigen retrieval Ki67 was developed
with 3,30-diaminobenzidine (Dako, Ely, Cambridgeshire, UK).
Stained slideswere blinded and imageswere taken on aNikon
Eclipse E600 (Shinagawa, Tokyo, Japan). For image quantiﬁ-
cation of F4/80 staining, 20 nonoverlapping images were
photographed at 200. The extent of 3,30-diaminobenzidine
(DAB) staining was quantiﬁed using image analysis software
(Adobe Photoshop CS6). For CYPD2 quantiﬁcation, images
were quantiﬁed using image analysis software (Adobe Pho-
toshop CS6, Adobe, San Jose, CA). For Ki67 quantiﬁcation, 20
serial nonoverlapping images were photographed at 400,
and then hepatocytes were identiﬁed by assessment of
morphology.
Flow Cytometry
Liver was digested in 2 mg/mL collagenase D (Sigma-
Aldrich) at 37C for 30 minutes and then passed through a
100-mm ﬁlter. A 7-minute 50g spin was performed to
remove hepatocytes. Further puriﬁcation of non-
parenchymal cells was performed using 30% Percoll
(Sigma) gradient. Cells were stained with ﬁxable viability
dye eFluor 780 and then incubated with Fc block (Trust-
ainfcX; Biolegend), before staining with CD45 (clone:30F11,
AF700; Biolegend), F480 (clone:BM8, PECy7; Biolegend),
CD11b (clone:RM208, ﬂuorescein isothiocyanate; Invi-
trogen, Waltham, MA), Ly6C (clone:HK1.4, PerCP/Cy5.5;
Biolegend), dump gate (PE: CD3 [clone:17A2, PE]; Bio-
legend), CD19 (clone:6D5, PE; Biolegend), Siglec F (clo-
ne:E502440, PE; BD Biosciences, Franklin Lakes, NJ), and
Ly6G (clone:IA8, PE; BD Biosciences). For the proliferation
assay, cells were ﬁxed and permeabilized using the BD
Pharmingen bromodeoxyuridine ﬂow kit and then stained
with antibromodeoxyuridine (ﬂuorescein isothiocyanate;
BD Pharmingen) and Ki67 (eF660; eBioscience, San Diego,
CA). Flow cytometry was performed using the LSR Fortessa
(BD Biosciences).
Quantiﬁcation of mRNA
Quantiﬁcation of mRNA levels by real-time
reverse-transcription polymerase. RNA extraction kits
(Qiagen, Hilden, Germany) were used to extract RNA from
whole tissue. Predesigned validated primer sets for macro-
phage receptor with collagenous structure, macrophage
scavenging receptor 1, mannose receptor, interleukin 6,
oncostatin M, tumor necrosis factor, interferon g, inter-
leukin 10, and glyceraldehyde-3-phosphate dehydrogenase
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were purchased from Qiagen (Qiagen Quantitect Primers).
Quantitative real-time polymerase chain reaction was per-
formed using Express SYBR Green (Qiagen, UK). Gene
expression was calculated relative to glyceraldehyde-3-
phosphate dehydrogenase for each sample. Gene array at
6 hours after CSF1-Fc administration was performed using
cytokine and chemokine array RT2 proﬁler polymerase
chain reaction arrays and analyzed using the online RT2
proﬁler polymerase chain reaction array data analysis
(version 3.5; Qiagen, UK), and presented by Volcano plot.
Affymetrix (Santa Clara, CA) Mouse gene 1.1 ST array data
were accessed from the Gene Expression Omnibus website
and analyzed using GEO2R, with Benjamini and Hochberg
(false-discovery rate) correction applied to the entire data
series.
Phagocytosis Assay
Under 2% isoﬂuorane anesthesia, the inferior vena cava
was cannulated and 100 mL of red ﬂuorescent bead solu-
tion (1:5 latex beads 1.0 mm, ﬂuorescent red; Sigma-
Aldrich) was infused through the cannula (1:2 solution
for assay after paracetamol injury). Ex vivo ﬂuorescent
quantiﬁcation was performed at 1 minute after bead in-
jection and 15 mL 0.9% NaCl ﬂush (Supplementary
Figure 5A). For assessment of bead clearance from the
circulation 20 mmol/L of blood was removed from the
cannula every 2 minutes starting from 1 minute after in-
jection for 15 minutes and immediately ﬁxed (300 mL
ﬂuorescence-activated cell sorter–lyse; BD Biosciences).
After the 15-minute time point the mice were perfused
with 15 mL 0.9% saline through the inferior vena cava
cannula with portal vein outﬂow. Organs then were
removed (liver, spleen, lungs, kidney, brain) and imaged
using a Kodak (Rochester, NY) In-Vivo Multispectral FX
image station (excitation, 550 nm; emission, 600 nm;
exposure, 1 s; F-stop, 2.8). Subsequently, blood samples
were analyzed using a LSR-Fortessa ﬂow cytometer (BD
Biosciences) with ﬂuorescent beads detected on the blue
channel (B695/40) by a 1-minute sample collection on the
low-ﬂow rate setting. Multiphoton imaging was performed
using a Zeiss (Oberkochen, Germany) LSM7 MP with
Coherent Chameleon Ti:Sa laser.
Mouse Serum Analyses
Serum biochemistry assays were performed using
commercially available kits by a biochemist, including ALT
(Alpha Laboratories, Eastleigh, Hampshire, UK), alkaline
phosphatase (Roche Diagnostics, Risch-Rotkreuz,
Switzerland), total bilirubin (Alpha Laboratories), and al-
bumin (Alpha Laboratories). Total serum protein was
analyzed using the Bradford assay as previously described.8
Serum cytokines and chemokines were analyzed using
the Milliplex mouse cytokine/chemokine array (Merck-
Millipore, Darmstadt, Germany) in collaboration with a
Merck-Millipore biomarker specialist.
Hepatocyte Metabolic and Toxicity Assays
Human and mouse hepatocytes were isolated from liver
tissue as previously described.9,10 The glutathione depletion
assay, MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethox-
yphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) reduction assay,
and lactate dehydrogenase (LDH) leakage assay were per-
formed on human and mouse hepatocytes as previously
described.10
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(3.9) 2
CLM (6)
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HCC (2)
Cholangio (1)
1 1915(1543) 0/10
3-5 segments 28 61.5(10.4) 14:14
27.4
(5.7) 2
CLM (22)
Cyst (3)
Carcin. (2)
Abscess (1)
1 1063(1425) 0/28
<3 segments 17 63.9(10.3) 17:3
29.9
(5.2) 2
CLM (10)
HCC (4)
Haemang. (2)
Mets ?prim (1)
0 1011(777) 0/17
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Age Sex BMI ASA Diagnosis Extent of resection
Blood 
loss
(mls)
Post op hepatic 
failure Outcome
1 65 F 30.5 2 Carcinoid 6 segments(1,4,5,6,7,8) 2500
Bilirubin >54 and hepatic 
encephalopathy (grade 3)
Improved with 
supportive care
2 63 M 29 2
Colorectal 
liver 
metastasis
4 segments
(5,6,7,8) 500
Bilirubin >54, ascites and 
hepatic encephalopathy 
(grade 1)
Improved with 
supportive care
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For healthy controls see Supplementary Figure 8
Supplementary Figure 1. Supporting details for partial hepatectomy in humans. (A) Details of patients undergoing partial
hepatectomy categorised according to extent of resection (n¼55). (B) Dot plot showing blood loss versus serum CSF1 (no
relationship between these variables). (C) Details of patients developing postoperative liver failure (n¼2). Blood loss according
to extent of resection. (D) Hepatic CSF1 gene expression following partial hepatectomy in mice.
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Outcome n Age M:F ALT(U/L) PT (Sec)
Creatinine 
(μmol/L)
Acetyl-
HMGB1 
(ng/ml)
CSF1 
(ng/ml)
Survived 47 37(13) 21:26
4412
(3764)
38.7
(30.0)
129.8
(120.1)
0.46
(1.52)
7.81
(2.82)
Died/Liver transplantation 31 42(15) 10:21
4814
(3060)
70.0
(38.8) 213.8(112.8)
4.49
(5.70)
3.69
(2.49)
Healthy controls
n Age M:F Acetyl-HMGB1 (ng/ml) CSF1 (ng/ml)
50 35(10) 4/5
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(0.09)
0.22
(0.12)
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1370
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(1.8)
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2.06
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(1.08)
c
S I
R S
< 2
S I
R S
> 2
0
5
1 0
1 5
2 0
S
e
ru
m
C
S
F
1
(n
g
/m
l) *
K C C n o K C C ye s
0
5
1 0
1 5
2 0
S
e
ru
m
C
S
F
-1
(n
g
/m
l)
H e a lth y
v o lu n te e r
****
0 5 0 1 0 0
0
5 0
1 0 0
1 0 0 % - S p e c if ic ity %
S
e
n
s
it
iv
it
y
%
A U C : 0 .8 6
S E : 0 .0 4 5
p < 0 .0 0 0 1
K C C y e s o r n o
d
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Supplementary Figure 2. Supporting details for acetaminophen intoxication in humans. (A) Details of acetaminophen
intoxication patients presenting to the specialist liver unit with acute liver failure grouped according to survivors versus those
who subsequently required liver transplantation or died (patient cohort and acetyl-HMGB1 values as per Antoine et al.18;
healthy control data also shown). (B) Serum CSF1 level in healthy volunteers and in patients following paracetamol intoxication
on arrival to a specialist liver unit grouped according to whether patients subsequently deteriorated to meet the King’s college
criteria or not (KCC no: n¼45; KCC yes: n¼33). (C) Receiver operator characteristic curves based on serum CSF1 level in
patients according to King’s College Criteria and also patients who subsequently survived or died/required liver trans-
plantation. (D) Serum CSF1 level according to systemic inﬂammatory response score (SIRS) on admission to the tertiary
referral hospital with acute liver failure (NB. SIRS scores available for n¼60). (E) Details of patients from ﬁrst presentation to
hospital following acetaminophen intoxication (n¼10 per group; patients randomly selected from patient cohort as per Antoine
et al.18). (F) Immunhistochemistry for the CSF1 protein in explant liver following acetaminophen intoxication. (G) Hepatic CSF1
gene expression following acetaminophen intoxication in mice (One way ANOVA with Bonferroni post hoc). (H) Deviance
residuals for logistic regression models. (I) Analysis of deviance comparing combined Log(acetyl-HMGB1) þ CSF1 model
(Model 1) and CSF1 alone (Model 2). *P < .05, ** P < .01, *** P < .001, **** P < .0001.
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Supplementary Figure 2. (continued).
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Symbol Log2(FC) p Value
Adipoq 1.22 1.9E-01
Bmp2 0.04 7.0E-01
Bmp4 0.32 5.9E-01
Bmp6 0.06 9.0E-01
Bmp7 -0.90 9.1E-03
Ccl1 -0.23 2.5E-01
Ccl11 1.32 9.7E-02
Ccl12 4.92 2.8E-02
Ccl17 -0.20 8.2E-01
Ccl19 0.65 9.6E-03
Ccl2 4.34 3.7E-02
Ccl20 -0.11 5.2E-01
Ccl22 -1.39 5.3E-02
Ccl24 0.78 2.6E-01
Ccl3 3.19 1.1E-02
Ccl4 2.61 3.3E-03
Ccl5 -0.26 3.4E-01
Ccl7 6.58 2.9E-02
Cd40lg 0.74 1.9E-01
Cd70 -0.23 2.5E-01
Cntf 2.34 4.0E-02
Csf1 -0.75 4.6E-02
Csf2 -0.23 2.5E-01
Csf3 -0.23 2.5E-01
Ctf1 -1.06 2.8E-02
Cx3cl1 -0.29 7.3E-01
Cxcl1 2.51 1.2E-01
Cxcl10 1.46 8.6E-02
Cxcl11 1.23 2.0E-01
Cxcl12 -0.33 2.8E-01
Cxcl13 2.48 3.5E-02
Cxcl16 0.55 1.2E-01
Cxcl3 -0.23 2.5E-01
Cxcl5 0.40 4.3E-01
Cxcl9 2.15 8.1E-02
Fasl 1.00 2.8E-01
Gpi1 -1.01 1.5E-01
Hc 1.60 6.5E-02
Ifna2 -0.28 1.9E-01
Ifng 0.97 2.4E-01
Il10 1.23 9.8E-02
Il11 -0.23 2.5E-01
Il12a 0.35 3.7E-01
Il12b 1.62 5.4E-02
Il13 0.05 7.3E-01
Il15 1.09 1.1E-01
Il16 0.06 7.6E-01
Il17a -0.23 2.5E-01
Il17f -0.40 2.0E-01
Il18 1.23 8.2E-02
Il1a 2.21 7.7E-02
Il1b 1.99 6.5E-02
Il1rn 0.77 2.2E-01
Il2 -0.23 2.5E-01
Il21 -0.23 2.5E-01
Il22 -0.23 2.5E-01
Il23a 0.55 2.0E-01
Il24 -0.23 2.5E-01
Il27 0.33 4.6E-01
Il3 -0.23 2.5E-01
Il4 0.56 2.4E-01
Il5 -0.52 4.9E-02
Il6 2.92 2.7E-02
Il7 3.26 3.1E-02
Il9 -0.23 2.5E-01
Lif -0.49 3.5E-02
Lta -0.26 2.1E-01
Ltb -0.91 1.9E-01
Mif -0.40 2.3E-01
Mstn -0.23 2.5E-01
Nodal -0.35 6.5E-01
Osm -0.49 3.1E-01
Pf4 1.30 7.3E-02
Ppbp 1.13 6.2E-01
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Tgfb2 0.11 8.2E-01
Thpo -1.04 2.5E-01
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Xcl1 1.09 1.1E-01
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Supplementary Figure 3. Supporting details for CSF1-Fc treatment of uninjured mice. (A) Array data 6 hours following CSF1-
Fc administration in uninjured mice (n¼4/group). (B) TUNNEL immunohistochemistry following PBS control or CSF1-Fc
administration (positive control DNAse treated section). (C) Organ weight relative to mean of control group following 2 days
treatment with PBS control (black solid circles), or CSF1-Fc (grey hollow circles). (D) Representative F4/80 immunohisto-
chemistry following 2 days treatment with PBS control or CSF1-Fc.
Supplementary Figure 3. (continued).
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Supplementary Figure 4. Supporting details for CSF1-Fc treatment of uninjured mice. (A) Representative ﬂow cytometry dot
plot of BRDU and Ki67 expression in resident (red) and inﬁltrating (blue) macrophages. (B) Representative dual immunohis-
tochemistry F4/80 (green) and BRDU or Ki67 (red) Day 2 following CSF1-Fc administration or control. (C) Number of hepatic
dendritic cells (CD11c/MHCII þve), eosinophils and neutrophils in control (black circles) and CSF1- Fc (grey circles) treated
mice relative to mean of control group. (D) Number of Ly6C low, intermediate and high monocytes in wild type and Ccr2-/-
mice following 2 days treatment with CSF1-Fc or PBS control (two way ANOVA with Bonferroni post hoc). (E) Number of
hepatic dendritic cells (CD11c/MHCII þve), eosinophils and neutrophils in control (black circles) and CSF1-Fc (grey circles)
treated mice relative to mean of control group. *P < .05, ** P < .01, *** P < .001, **** P < .0001.
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Supplementary Figure 5. Supporting data for partial hepatectomy model. (A) Quantiﬁcation CYPD2 immunoﬂuorescence (red)
per 20x HPF/mouse (control n¼8; CSF1-Fc n¼7; t test). (B) Number of mitotic ﬁgures and Ki67 positive hepatocytes per high
powered ﬁeld following following partial hepatectomy and either GW2580, AFS98 or CSF1-Fc administration versus control
(vehicle gavage, rat IgG2a, PBS; n¼8/group; 2-way ANOVA comparing intervention with relevant control, Bonferroni post hoc).
(C) Hepatic gene cytokine expression at Day 2 following partial hepatectomy and either GW2580, AFS98 or CSF1-Fc
administration versus control (vehicle gavage, rat IgG2a, PBS; n¼8/group; 2-way ANOVA comparing intervention with rele-
vant control, Bonferroni post hoc). (D) Hepatic MMP and UPAR (urokinase plasminogen activator) gene expression Day 2
following partial hepatectomy and either GW2580, AFS98 or CSF1-Fc administration versus control (vehicle gavage, rat IgG2a,
CSF1-Fc; n¼8/group; 2-way ANOVA comparing intervention with relevant control, Bonferroni post hoc). (E) Exvivo ﬂuorescent
imaging of organs 1 minute following injection of ﬂuorescent micro beads in to the inferior vena cava. (F) Flow cytometry plots
demonstrating bead and cell gating of blood samples following ﬂuorescent microbead injection in to the inferior vena cava. (G)
Representative ﬂow plots of blood sampled from the inferior vena cava at 1 minute and 15 minutes following injection of
ﬂuorescent microbeads in to the circulation. Gating strategies including total ﬂuorescent bead count (“Total beads”) and bead
count with in blood cellular populations (“Cells þ beads”). *P < .05, ** P < .01, *** P < .001, **** P < .0001.
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Supplementary Figure 6. Supporting details for acetaminophen intoxication in mice, (A) Quantiﬁcation of area of necrosis and
cellular inﬁltrate at Day 2, 3 and 4 following acetaminophen intoxication. (B) Hepatic macrophage phenotype D3 following
acetaminophen administration (F4/80þ/CD11b- ¼ resident macrophage population; F4/80-/CD11bþ ¼ inﬁltrating macrophage
population. (C) Serum cytokine array Day 4 following partial hepatectomy and either PBS control or CSF1-Fc treatment (2-way
ANOVA and Bonferroni post hoc ns). (D) Hepatic albumin gene expression relative to GAPDH comparing control and CSF1-Fc
treated mouse liver (n¼8/group; t test ns). (E) Total protein concentration at D3. (F) Serum ALT following acetaminophen
intoxication in control (dotted line) and CSF1-Fc treated (solid line) mice. *P < .05, ** P < .01, *** P < .001, **** P < .0001.
1909.e13 Stutchﬁeld et al Gastroenterology Vol. 149, No. 7
Supplementary Figure 7. No evidence of direct hepatocyte effects of CSF1-Fc. (A) MTS reduction assay, LDH leakage assay
and GSH content on mouse hepatocytes exposed to APAP and increasing concentration of CSF1-Fc showing no dose related
effect. (B) MTS reduction assay, LDH leakage assay and GSH content on human hepatocytes exposed to APAP and
increasing concentration of CSF1-Fc showing no dose related effect. (C) Whole liver assessment of CYP2E1 expression
relative to actin assessed via Western blot and mRNA day 3 post acetaminophen intoxication with control or CSF1-Fc
treatment.
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